Sensus Healthcare, Inc. (NASDAQ:SRTS) Shares Bought by Renaissance Technologies LLC

Renaissance Technologies LLC raised its holdings in Sensus Healthcare, Inc. (NASDAQ:SRTS) by 34.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 391,534 shares of the company’s stock after acquiring an additional 100,294 shares during the period. Renaissance Technologies LLC’s holdings in Sensus Healthcare were worth $2,087,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Chapin Davis Inc. acquired a new stake in Sensus Healthcare in the 2nd quarter valued at about $53,000. Creekmur Asset Management LLC acquired a new stake in Sensus Healthcare in the 4th quarter valued at about $83,000. Hillsdale Investment Management Inc. acquired a new stake in shares of Sensus Healthcare during the 1st quarter worth approximately $155,000. Acadian Asset Management LLC increased its holdings in shares of Sensus Healthcare by 578.6% during the 2nd quarter. Acadian Asset Management LLC now owns 45,124 shares of the company’s stock worth $239,000 after buying an additional 38,474 shares during the last quarter. Finally, Sachetta LLC increased its holdings in shares of Sensus Healthcare by 12.9% during the 2nd quarter. Sachetta LLC now owns 118,354 shares of the company’s stock worth $631,000 after buying an additional 13,544 shares during the last quarter. Institutional investors and hedge funds own 25.30% of the company’s stock.

Sensus Healthcare Stock Performance

NASDAQ:SRTS opened at $6.10 on Thursday. The stock has a market capitalization of $100.00 million, a P/E ratio of 21.03 and a beta of 1.05. The company has a 50 day moving average price of $6.19 and a 200 day moving average price of $5.25. Sensus Healthcare, Inc. has a fifty-two week low of $1.79 and a fifty-two week high of $7.18.

Sensus Healthcare (NASDAQ:SRTS) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.07. The firm had revenue of $9.24 million during the quarter, compared to analysts’ expectations of $7.00 million. Sensus Healthcare had a net margin of 18.27% and a return on equity of 13.46%. During the same quarter last year, the company posted ($0.02) EPS. Research analysts forecast that Sensus Healthcare, Inc. will post 0.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SRTS has been the subject of a number of recent analyst reports. Roth Capital upgraded shares of Sensus Healthcare to a “strong-buy” rating in a report on Friday, July 12th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Sensus Healthcare in a report on Monday, August 12th.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.